Safety, Tolerability and Pharmacokinetics Study in Patients with Pulmonary Arterial Hypertension (PAH) Temporarily Switching from Oral to IV Selexipag

被引：3
|
作者：
Klose, H. [1 ]
Chin, K. [2 ]
Ewert, R. [3 ]
Gall, H. [4 ]
Parambil, J. [5 ]
Poch, D. [6 ]
Seyfarth, H. [7 ]
Axelsen, L. [8 ]
Schmitz, S. Hsu [9 ]
Stein, C. [10 ]
Preston, I. [11 ]
机构：
[1] Univ Med Ctr Hamburg Eppendorf, Dept Resp Med, Ctr Oncol, Hamburg, Germany
[2] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA
[3] Ernst Moritz Arndt Univ Greifswald, Dept Resp Med, Clin Internal Med, Greifswald, Germany
[4] UGMLC, Internal Med, Giessen, Germany
[5] Cleveland Clin, Dept Pulm Allergy & Crit Care Med, Resp Inst, Cleveland, OH 44106 USA
[6] Univ Calif San Diego, Dept Pulm Crit Care, San Diego, CA 92103 USA
[7] Univ Leipzig, Dept Resp Med, Leipzig, Germany
[8] Actel Pharmaceut Ltd, Clin Pharmacol, Allschwil, Switzerland
[9] Actel Pharmaceut Ltd, Biostat, Allschwil, Switzerland
[10] Actel Pharmaceut Ltd, Clin Sci, Allschwil, Switzerland
[11] Tufts Univ, Sch Med, Tufts Med Ctr, Pulm Crit Care & Sleep Div, Boston, MA 02111 USA
来源：
JOURNAL OF HEART AND LUNG TRANSPLANTATION | 2019年 / 38卷 / 04期
关键词：
D O I：
10.1016/j.healun.2019.01.1247
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1237
引用
收藏
页码：S490 / S490
页数：1
相关论文
共 50 条
  • [41] Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
    Nazzareno Galiè
    Sean Gaine
    Richard Channick
    J. Gerry Coghlan
    Marius M. Hoeper
    Irene M. Lang
    Vallerie V. McLaughlin
    Cheryl Lassen
    Lewis J. Rubin
    Shu-Fang Hsu Schmitz
    Olivier Sitbon
    Victor F. Tapson
    Kelly M. Chin
    Advances in Therapy, 2022, 39 : 796 - 810
  • [42] Effect of selexipag on long-term outcomes in key subgroups of patients with pulmonary arterial hypertension (PAH): GRIPHON study results
    Sitbon, Olivier
    Channick, Richard
    Chin, Kelly
    Frey, Aline
    Galie, Nazzareno
    Ghofrani, Hossein-Ardeschir
    Hoeper, Marius M.
    Lang, Irene
    Le Brun, Franck-Olivier
    McLaughlin, Vallerie
    Preiss, Ralph
    Rubin, Lewis J.
    Simonneau, Gerald
    Tapson, Victor
    Gaine, Sean
    EUROPEAN RESPIRATORY JOURNAL, 2015, 46
  • [43] Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension
    Galie, Nazzareno
    Gaine, Sean
    Channick, Richard
    Coghlan, J. Gerry
    Hoeper, Marius M.
    Lang, Irene M.
    McLaughlin, Vallerie V.
    Lassen, Cheryl
    Rubin, Lewis J.
    Hsu Schmitz, Shu-Fang
    Sitbon, Olivier
    Tapson, Victor F.
    Chin, Kelly M.
    ADVANCES IN THERAPY, 2022, 39 (01) : 796 - 810
  • [44] Pharmacokinetics and Safety of Ambrisentan in Pediatric Patients with Pulmonary Arterial Hypertension
    Ivy, D.
    Rosenzweig, E. B.
    Calderbank, M.
    Coleman, B.
    Miller-Reed, K.
    Geppner, J.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2010, 181
  • [45] Uptitration of Pulmonary Arterial Hypertension Therapies: Transition From Oral Selexipag to Parenteral Treprostinil
    Krishnan, M.
    Gomberg-Maitland, M.
    Dias-Douglas, J. M.
    Sherner, J.
    Choi, J.
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2024, 43 (04): : S560 - S560
  • [46] The impact of time from diagnosis at baseline on long-term outcome in the GRIPHON Study: Selexipag in pulmonary arterial hypertension (PAH)
    Gaine, S.
    Sitbon, O.
    Channick, R.
    Chin, K.
    Di Scala, L.
    Galie, N.
    Hoeper, M. M.
    McLaughlin, V
    Preiss, R.
    Rubin, L.
    Simonneau, G.
    Tapson, V
    Ghofrani, H. A.
    Lang, I
    PNEUMOLOGIE, 2020, 74 : S63 - S63
  • [47] Safety And Tolerability Of Outpatient Transition Of Parenteral And Inhaled Treprostinil To Oral Treprostinil In Patients With Pulmonary Arterial Hypertension
    Khan, A. A.
    Ackerbauer, K.
    Tandon, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [48] Efficacy, safety and tolerability of bosentan in Chinese patients with pulmonary arterial hypertension
    Jing, Zhi-Cheng
    Strange, Geoff
    Zhu, Xian-Yang
    Zhou, Da-Xin
    Shen, Jie-Yan
    Gu, Hong
    Yang, Zhen-Kun
    Pan, Xin
    Xiang, Mei-Xiang
    Yao, Hua
    Zhao, Dong-Bao
    Dalton, Brad S.
    Zhang, Zhuo-Li
    Wang, Yong
    Cheng, Xian-Sheng
    Yang, Yue-Jin
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2010, 29 (02): : 150 - 156
  • [49] Efficacy and safety of selexipag in real-life in patients with pulmonary arterial hypertension: early results of RAMPHA study
    Bravo Marques, R.
    Becerra Munoz, V
    Walls Rodriguez, A. J.
    Espildora Hernandez, F.
    Callejas Rubio, J. L.
    Garcia De Polavieja, J. I. Morgado
    Martin Suarez, I
    Bonilla Palomas, J. L.
    Rivas-Ruiz, F.
    Recio Mayoral, A.
    EUROPEAN HEART JOURNAL, 2022, 43 : 1932 - 1932
  • [50] Transition from treprostinil to selexipag in patients with pulmonary arterial hypertension: Case series
    Fanous, Sherif M.
    Janmohamed, Munir
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2018, 75 (23) : 1877 - 1881
12345